Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
An announcement from Genus plc ( (GB:GNS) ) is now available.
Genus plc reported strong trading results for FY25, with underlying group performance aligning with expectations. The company achieved double-digit growth in PIC adjusted operating profit, bolstered by a £3.7 million milestone receipt following FDA approval of its PRRS Resistant Pig gene edit. ABS exceeded expectations in the second half, driven by the Value Acceleration Programme, which contributed £8.5 million in benefits. As a result, Genus expects its adjusted profit before tax to be at least £72 million, reflecting strong cash flow and reduced leverage. The FDA approval marks a significant milestone for Genus, enhancing its market position in the animal genetics industry and signaling potential growth opportunities.
The most recent analyst rating on (GB:GNS) stock is a Hold with a £1850.00 price target. To see the full list of analyst forecasts on Genus plc stock, see the GB:GNS Stock Forecast page.
Spark’s Take on GB:GNS Stock
According to Spark, TipRanks’ AI Analyst, GB:GNS is a Neutral.
Genus plc’s overall stock score reflects moderate financial performance with strengths in strategic initiatives and corporate developments. However, valuation concerns and cautious technical indicators temper the outlook, suggesting challenges in achieving significant upward momentum.
To see Spark’s full report on GB:GNS stock, click here.
More about Genus plc
Genus plc is a world-leading animal genetics company that applies biotechnology to advance animal breeding and genetic improvement. The company sells value-added products for livestock farming and food producers, focusing on dairy, beef, and pork food production sectors. Genus operates globally under the trademarks ‘ABS’ for dairy and beef cattle and ‘PIC’ for pigs, offering superior genetics through semen, embryos, and breeding animals. The company is headquartered in Basingstoke, UK, with operations in over twenty-five countries and research laboratories in Madison, Wisconsin, USA.
Average Trading Volume: 177,743
Technical Sentiment Signal: Hold
Current Market Cap: £1.46B
For detailed information about GNS stock, go to TipRanks’ Stock Analysis page.